These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 34510001)

  • 1. Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances.
    Chong JR; Ashton NJ; Karikari TK; Tanaka T; Schöll M; Zetterberg H; Blennow K; Chen CP; Lai MKP
    J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1231-1241. PubMed ID: 34510001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of fluid biomarkers in Alzheimer's Disease.
    Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J
    Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.
    Hampel H; Mitchell A; Blennow K; Frank RA; Brettschneider S; Weller L; Möller HJ
    J Neural Transm (Vienna); 2004 Mar; 111(3):247-72. PubMed ID: 14991453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
    Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of plasma candidate biomarkers of Alzheimer's Disease.
    Lewczuk P; Łukaszewicz-Zając M; Kornhuber J; Mroczko B
    Neurol Neurochir Pol; 2024; 58(4):363-379. PubMed ID: 39093167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in blood biomarkers for Alzheimer disease (AD): A review.
    Assfaw AD; Schindler SE; Morris JC
    Kaohsiung J Med Sci; 2024 Aug; 40(8):692-698. PubMed ID: 38888066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
    Brickman AM; Manly JJ; Honig LS; Sanchez D; Reyes-Dumeyer D; Lantigua RA; Lao PJ; Stern Y; Vonsattel JP; Teich AF; Airey DC; Proctor NK; Dage JL; Mayeux R
    Alzheimers Dement; 2021 Aug; 17(8):1353-1364. PubMed ID: 33580742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer's Disease.
    Sharma A; Angnes L; Sattarahmady N; Negahdary M; Heli H
    Biosensors (Basel); 2023 Jul; 13(7):. PubMed ID: 37504140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
    Rauchmann BS; Schneider-Axmann T; Perneczky R;
    J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood-Based Oligomeric and Other Protein Variant Biomarkers to Facilitate Pre-Symptomatic Diagnosis and Staging of Alzheimer's Disease.
    Williams SM; Schulz P; Rosenberry TL; Caselli RJ; Sierks MR
    J Alzheimers Dis; 2017; 58(1):23-35. PubMed ID: 28372328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.
    Hampel H; Goernitz A; Buerger K
    Brain Res Bull; 2003 Aug; 61(3):243-53. PubMed ID: 12909294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting.
    Zeng X; Chen Y; Sehrawat A; Lee J; Lafferty TK; Kofler J; Berman SB; Sweet RA; Tudorascu DL; Klunk WE; Ikonomovic MD; Pfister A; Zetterberg H; Snitz BE; Cohen AD; Villemagne VL; Pascoal TA; Kamboh MI; Lopez OI; Blennow K; Karikari TK
    Mol Neurodegener; 2024 May; 19(1):40. PubMed ID: 38750570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A New Serum Biomarker Set to Detect Mild Cognitive Impairment and Alzheimer's Disease by Peptidome Technology.
    Abe K; Shang J; Shi X; Yamashita T; Hishikawa N; Takemoto M; Morihara R; Nakano Y; Ohta Y; Deguchi K; Ikeda M; Ikeda Y; Okamoto K; Shoji M; Takatama M; Kojo M; Kuroda T; Ono K; Kimura N; Matsubara E; Osakada Y; Wakutani Y; Takao Y; Higashi Y; Asada K; Senga T; Lee LJ; Tanaka K
    J Alzheimers Dis; 2020; 73(1):217-227. PubMed ID: 31771070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer's disease.
    Park SA; Han SM; Kim CE
    Exp Mol Med; 2020 Apr; 52(4):556-568. PubMed ID: 32284537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers of Alzheimer's disease: the present and the future.
    Lehmann S; Delaby C; Touchon J; Hirtz C; Gabelle A
    Rev Neurol (Paris); 2013 Oct; 169(10):719-23. PubMed ID: 24021316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.